Real-world outcomes of rivaroxaban treatment in patients with nonvalvular atrial fibrillation and worsening renal function.
CONCLUSIONS: No association between WRF and occurrence of any bleeding, major bleeding, and stroke/systemic embolism/myocardial infarction was observed in patients with AF on rivaroxaban treatment during 1-year follow-up in real-world clinical practice. Clinicaltrials.gov: NCT01582737.
PMID: 31371191 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - Category: Cardiology Authors: Nakagawara J, Ikeda T, Ogawa S, Kitazono T, Minematsu K, Miyamoto S, Murakawa Y, Takeichi M, Kidani Y, Okayama Y, Sunaya T, Sato S, Yamanaka S Tags: J Cardiol Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Heart | Heart Attack | Japan Health | Stroke | Study